Awarener easy mode Awarener analytic mode

Fundamental analysis: Concert Pharmaceuticals, Inc. (CNCE)

Awarener score: 3.9

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (Very poor), the business stability (Bottom) and growth (Superb), and the company's inclination to return cash to the stockholders (Lacking).

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 5.5

  • Business has been growing at an extremely fast pace. It's been top tier when measured against peer companies.
  • Concert Pharmaceuticals, Inc. business varies wildly, ups and downs could be very frequent. It's very risky. It looks bottom tier against rivals.

Margins score: 1.2

  • CNCE profit margins -on goods and services sold- are usually extremely poor. They stand somewhat worse than rival companies.
  • Business profit on sales tends to be pauper. It's substantially worse when measured against competitors.
  • Profits on sales made -available to repay debt and purchase properties- are usually destitute. They remain in a very weak position compared to peers.
  • Earnings -before income taxes and interests on loans taken- tend to be pauper in relation to total revenues. They're still worse than most similar companies.
  • Profits -before income taxes- are usually destitute considering total sales, and remain substantially worse when measured against rivals.
  • Total net profit tends to be pauper when confronted to sales. Company stands substantially worse when measured against comparable firms.

Growth score: 1.1

  • Concert Pharmaceuticals, Inc. profit -on goods and services sold- has been shrinking. It's been in a very weak position compared to competitors.
  • In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
  • In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
  • In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
  • In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
  • In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
  • The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 3.7

  • CNCE had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
  • Research and development expenses consume a substantial portion of revenues. It's more than average in relation to competitors.
  • The company shows business growth in relation to research and development efforts. It stands impressive in relation to rival companies.

Profitability score: 3.0

  • Concert Pharmaceuticals, Inc. usually gets meagre returns on the resources it controls. It proves more than average in relation to peer firms.
  • The company normally gets meagre proceeds -on the resources directly invested in the business-. They remain excellent in relation to similar companies.
  • There's usually little profitability -in relation to owned resources-. It ranks more than average in relation to competitors.
  • In the past, got meagre returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's great when measured against comparable enterprises.

Usage of Funds score: 2.6

  • CNCE on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands great when measured against rival firms.
  • The company is usually replacing most of the property, plant, and equipment that gets old, and saving a little funds for something else, which is below average when measured against industry peers.
  • In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
  • The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
  • As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
  • The company usually significantly enlarges the pool of investors, resulting in more mouths feeding on the pie of profits. It remains excellent in relation to peer enterprises.
  • Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
  • We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 5.6

  • Concert Pharmaceuticals, Inc. has no intangible assets (like brands and goodwill) according to accounting books, which is safest. It happens to be top tier when measured against peer companies.
  • The company has a lot more short-term resources than short-term obligations. There're no liquidity concerns. It turns to be close to average when compared to similar firms.
  • Roughly a tenth of resources controlled were provided for with financial debt. Creditors have minor claims on the company, and financial position is safe. It remains mediocre against rival firms.
  • Most resources controlled are already cash or short-term investments, which is best for liquidity. It looks similar to rivals.
  • For every dollar of short-term obligations, the company has a lot of dollars in cash and short-term receivables. It's rather normal in relation to peer firms.
  • For every dollar of short-term obligations, the company has a lot of dollars in cash and equivalents, which is slightly better than similar enterprises.
  • Usually, sales are on many months credit. It still ranks encouraging in relation to peers.
  • Days of inventory outstanding are not known. It comes up as a big question mark against competitors.
  • We could not gauge the normal operating cycle of the company. It happens to be a mystery against peers.
  • Unfortunately, we had not enough data to estimate the days of payables outstanding. It ranks unknown against industry peers.
  • Cash conversion cycle remains unknown, due to not having enough inputs. It's incomparable against similar companies.
  • To what extent normalized EBITDA covers interest expenses is not known. It stands impossible to compare against rival firms.
  • Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
  • The company didn't have revenues in the past twelve months. It must start having income to take advantage of used resources. It looks in good shape compared to similar firms.
  • The firm has yet to start reporting any sales. It's still better than most peer companies.

Valuation score: 3.2

  • Concert Pharmaceuticals, Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
  • Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains lacking compared to peers.
  • In the past twelve months, the company consumed funds. Either it reinvested significantly in the business or genuine fund generation might be struggling, which stands somewhat worse than similar companies.
  • The company usually consumes much more funds than can genuinely generate. Business needs are meet by borrowing money or consuming preexistent cash, which can only keep up until a certain limit. Unless the company is driving significant business growth, genuine profitability may be brought into question. It's still below average when measured against industry firms.
  • In the past twelve months, the company has enlarged the pool of investors by issuing new shares. Future profits need to be high enough to justify the measure, as the pie of earnings will now be split among somewhat more stockholders. It came up in good shape compared to peer ventures.
  • This company is a cash hoarder. It might be well poised to substantially increase stockholder payments, or to fund new business projects. It looks slightly better than similar enterprises.
  • Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
  • Comparing the current stock price with the past twelve-months revenues gives a huge relationship. The stock price might rely more on expectations and resources controlled than on anything else. It looks a slight improvement compared to rival firms.
  • The relation between the stock price and accounting book value is high, which may be good or bad depending on context. Run again in analytic mode if you want to dig deeper. The company remains somewhat worse than peer firms.
  • In the past twelve months, the operating business lost a lot of money. It happens to be encouraging in relation to industry peers.
  • In an alternate metric of bang for the buck, the company has usually shown a very low earnings power ability when measured against the current stock price and financial position. Profitability is in dispute. It's still a slight improvement compared to peer companies.

Total score: 3.2


CNCE logos

Company at a glance: Concert Pharmaceuticals, Inc. (CNCE)

Sector, industry: Healthcare, Biotechnology

Market Cap: 0.29 billions

Revenues TTM: unavailable

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Awarener score: 3.9

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (Very poor), the business stability (Bottom) and growth (Superb), and the company's inclination to return cash to the stockholders (Lacking).